Opinion|Videos|January 26, 2024
Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.
Advertisement
Episodes in this series
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
2
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
3
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
4
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
5